Literature DB >> 30334256

Evidence against a crucial role of renal medullary perfusion in blood pressure control of hypertensive rats.

Bożena Bądzyńska1, Iwona Baranowska1, Olga Gawryś1, Janusz Sadowski1.   

Abstract

KEY POINTS: The development of new effective methods of treating arterial hypertension is hindered by uncertainty regarding its causes. According to one widespread concept hypertension is caused by abnormal blood circulation in the kidney, specifically by reduction of blood flow through the kidney medulla; however, this causal relationship has never been rigorously verified. We investigated whether in rats with three different forms of experimental hypertension prolonged selective elevation of renal medullary blood flow using local infusion of the vasodilator bradykinin would lower arterial pressure. We found that increasing medullary blood flow by almost 50% did not result in alleviation of hypertension, which argues against a causal role of such changes in the control of arterial pressure and suggests that attempts at improving renal medullary circulation are not likely to be a promising approach to combating hypertension. ABSTRACT: The crucial role of renal medullary blood flow (MBF) in the control of arterial pressure (MAP) has been widely accepted but not rigorously verified. We examined the effects of experimental selective MBF elevation on MAP, medullary tissue hypertonicity and renal excretion in hypertensive rats. We used three hypertensive rat models: (1) rats with hypertension induced by chronic angiotensin II infusions (AngII model), (2) rats with hypertension induced by unilateral nephrectomy followed by high salt diet (HS/UNX), and (3) spontaneously hypertensive rats (SHR). In acute experiments, MBF (laser-Doppler measurement) was selectively increased with an intramedullary infusion of bradykinin (Bk) at 0.27 mg h-1  kg-1 BW over 4 h. MAP, renal artery blood flow (Transonic probe) and renal excretion parameters were measured simultaneously. In chronic studies with AngII and HS/UNX rats, Bk was infused over 2 weeks and MAP (telemetry probe) and renal excretion were repeatedly determined. In acute studies, with AngII, SHR and HS/UNX groups, Bk infusion caused a 47% increase in MBF (P < 0.01-0.001), whereas solvent infusion was without effect. During the experiments MAP decreased slightly and to the same extent with Bk and solvent infusion. Medullary tissue osmolality and [Na+ ] were lower in Bk- than in solvent-infused AngII rats and in SHR. Two weeks of intramedullary Bk infusion tested in AngII and HS/UNX rats did not alter MAP or renal excretion; though in the latter group a significant MBF increase and medullary hypertonicity decrease was observed. Since no decrease in MAP in hypertensive rats was seen with Bk-induced major renal medullary hyperperfusion or with a wash-out of medullary solutes, our data argue against a crucial role of MBF in the pathogenesis of arterial hypertension.
© 2018 The Authors. The Journal of Physiology © 2018 The Physiological Society.

Entities:  

Keywords:  arterial blood pressure; bradykinin; medullary hypertonicity; renal excretion; renal medullary blood flow

Mesh:

Substances:

Year:  2018        PMID: 30334256      PMCID: PMC6312421          DOI: 10.1113/JP276342

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  34 in total

Review 1.  Importance of the renal medullary circulation in the control of sodium excretion and blood pressure.

Authors:  David L Mattson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-01       Impact factor: 3.619

Review 2.  Mechanisms underlying the antihypertensive functions of the renal medulla.

Authors:  G Bergström; R G Evans
Journal:  Acta Physiol Scand       Date:  2004-08

3.  Tautology vs. physiology in the etiology of hypertension.

Authors:  Daniel A Beard
Journal:  Physiology (Bethesda)       Date:  2013-09

4.  Pressure natriuresis and renal medullary blood flow in dogs.

Authors:  D S Majid; M Godfrey; L G Navar
Journal:  Hypertension       Date:  1997-04       Impact factor: 10.190

5.  Renal intramedullary infusion of L-arginine prevents reduction of medullary blood flow and hypertension in Dahl salt-sensitive rats.

Authors:  N Miyata; A W Cowley
Journal:  Hypertension       Date:  1999-01       Impact factor: 10.190

6.  Uninephrectomy in young age or chronic salt loading causes salt-sensitive hypertension in adult rats.

Authors:  Mattias Carlström; Johan Sällström; Ole Skøtt; Erik Larsson; A Erik G Persson
Journal:  Hypertension       Date:  2007-04-16       Impact factor: 10.190

Review 7.  Reactive oxygen species as important determinants of medullary flow, sodium excretion, and hypertension.

Authors:  Allen W Cowley; Michiaki Abe; Takefumi Mori; Paul M O'Connor; Yusuke Ohsaki; Nadezhda N Zheleznova
Journal:  Am J Physiol Renal Physiol       Date:  2014-10-29

Review 8.  Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension.

Authors:  L Gabriel Navar; Minolfa C Prieto; Ryousuke Satou; Hiroyuki Kobori
Journal:  Curr Opin Pharmacol       Date:  2011-02-19       Impact factor: 5.547

9.  Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.

Authors:  Markus P Schlaich; Elisabeth Lambert; David M Kaye; Zygmunt Krozowski; Duncan J Campbell; Gavin Lambert; Jacqui Hastings; Anuradha Aggarwal; Murray D Esler
Journal:  Hypertension       Date:  2003-11-10       Impact factor: 10.190

10.  Differential action of bradykinin on intrarenal regional perfusion in the rat: waning effect in the cortex and major impact in the medulla.

Authors:  Bozena Badzyńska; Janusz Sadowski
Journal:  J Physiol       Date:  2009-06-15       Impact factor: 5.182

View more
  1 in total

1.  Further evidence against the role renal medullary perfusion in short-term control of arterial pressure in normotensive and mildly or overtly hypertensive rats.

Authors:  Bożena Bądzyńska; Iwona Baranowska; Janusz Sadowski
Journal:  Pflugers Arch       Date:  2021-03-02       Impact factor: 3.657

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.